New Gene Therapy Systems: Advancement in Drug Delivery

Courtesy of ARIAD Pharmaceuticals In the gene therapy system devised by Penn and ARIAD researchers, the adeno-associated virus is injected into the body to deliver the desired gene (top left), and a drug in pill form is given orally to activate gene expression (top right). Researchers demonstrated a strong correlation between the amount of drug administered and the resulting increase in the amount of protein produced (center). Scientists attempting to devise successful, efficient gene therapy

Written byEugene Russo
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Courtesy of ARIAD Pharmaceuticals In the gene therapy system devised by Penn and ARIAD researchers, the adeno-associated virus is injected into the body to deliver the desired gene (top left), and a drug in pill form is given orally to activate gene expression (top right). Researchers demonstrated a strong correlation between the amount of drug administered and the resulting increase in the amount of protein produced (center). Scientists attempting to devise successful, efficient gene therapy systems face three major challenges: transference, persistence, and regulation. First, they must deliver the desired gene into target cells and ensure that it remains in those cells for an extended period of time. They must then, in many cases, regulate that gene so that it's only active when needed. Two recent papers, one in the Jan. 1 issue of Science1 and another in the Jan. 19 issue of Proceedings of the National Academy of Sciences ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies